Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Biodesix Inc. (BDSX:NASDAQ), powered by AI.
Biodesix Inc. is currently trading at $14.94. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Biodesix Inc. on Alpha Lenz.
Biodesix Inc.'s P/E ratio is -2.3.
“Biodesix Inc. trades at a P/E of -2.3 (undervalued) with modest ROE of -337.3%.”
Ask for details →Biodesix Inc. is a leading biotechnology company specializing in diagnostic solutions. The primary function of the company is to offer innovative blood-based diagnostics that utilize multi-omics technology for personalized medicine in the field of lung cancer. With a focus on non-invasive testing, Biodesix aims to support clinical decision-making by providing fast and accurate diagnostic information that helps to optimize patient treatment strategies. The company plays a significant role in the healthcare and biotechnology sectors by improving patient outcomes through precision medicine. Biodesix’s portfolio includes proprietary tests that assist in the detection, diagnosis, and monitoring of lung cancer, catering primarily to healthcare providers and patients. The company’s solutions are a valuable part of the oncological toolkit, instrumental in guiding therapeutic decisions and influencing the overall treatment landscape in oncology. Positioned within the growing field of personalized healthcare, Biodesix Inc. contributes to the shift towards more tailored therapies and medicine, helping to advance the development of new cancer treatments and improve the quality of life for patients.
“Biodesix Inc. trades at a P/E of -2.3 (undervalued) with modest ROE of -337.3%.”
Ask for details →Biodesix Inc. (ticker: BDSX) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 273 employees. Market cap is $97M.
The current price is $14.94 with a P/E ratio of -2.26x and P/B of 4.64x.
ROE is -337.30% and operating margin is -48.03%. Annual revenue is $71M.